argenx SE (ARGX) financials

NASDAQ · Healthcare · Biotechnology · 1,863 employees · CEO Karen Massey

Price: $892.87 -0.55%
Market cap: $56.1B
Enterprise value: $53.2B
Last report: Q4 '26 filed 2026-09-30
Next report: 2027-02-25 EPS est. $7.70

Revenue (TTM)–– vs a year agoLast 4 quarters; bars = each quarter

Operating margin (TTM)–– vs a year agoOperating income –

Net income (TTM)–– vs a year agoAfter tax, incl. non-operating gains

Free cash flow (TTM)–– vs a year agoCapex –

Diluted EPS (TTM)–– vs a year agoSum of the last 4 quarters

Net cash$5.14B+32.2% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap: $56.1B
Revenue: –
Revenue growth: +53%
Profit margin: –
P/E: 42.4×
P/S: 12.7×
EV / EBITDA: 38.4×
Free cash flow: –
Net income: –
Revenue estimate: $6.35B
Earnings: 2027-02-25
Dividend: –

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

Net cash $5.14BCash + short-term investments $5.18B, debt incl. leases $47M; a year ago net cash $3.89B.

Last quarter: Q4 '26

Quarter ended 2026-09-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

	Q4 '26	Year ago	Change
Revenue	$1.72B	–	–
Gross margin	90.4%	–	–
Operating income	$485M	–	–
Operating margin	28.2%	–	–
Net income	$506M	–	–
Diluted EPS	$7.80	–	–
R&D	$503M	–	–

EPS vs consensus

last 8 reports

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Revenue by region

share of total

Segment	Q4 '26	y/y	Share	TTM	TTM y/y
United States	$606M	–	88.0%	–	–
U	–	–	–	–	–
C	–	–	–	–	–
EMEA	$50M	–	7.3%	–	–
Japan	$32.8M	–	4.8%	–	–
Countries Other Than United States And China	–	–	–	–	–
Other	–	–	–	–	–

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 4 quarters

cash flow statement

Free cash flow: –
Returned to shareholders / FCF: –

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years

	Now	5y average	Where today sits in the 5-year range
P/E (TTM)	42.4×	42.0× 2 of 5 years	39.8× – 44.2×
EV / EBITDA	38.4×	186.4× 2 of 5 years	36.7× – 336.1×
EV / Sales	11.9×	21.5×	11.6× – 48.2×
Price / FCF	50.7×	61.1× 1 of 5 years	61.1× – 61.1×
Price / Book	6.7×	6.7×	5.3× – 7.3×
FCF yield	2.0%	-1.9%	-4.7% – 1.6%
Return on invested capital	14.0%	-6.9%	-24.7% – 14.3%
Return on equity	16.9%	-3.1%	-25.2% – 17.6%

Analysts

Consensus target $1,133.33 (+26.9%)
range $861.00 – $1,400.00 · rating Buy

Strong buy1

Buy31

Hold4

Sell0

Strong sell0

Outlook

Analyst consensus for the coming fiscal years and what it implies at today's price.

Consensus estimates

Fiscal year	Revenue	Growth	EPS	Growth	P/E at today's price	Analysts (EPS)
FY2026	$6.35B	+52.8%	$28.51	+45.2%	31.3×	9
FY2027	$7.96B	+25.4%	$37.08	+30.1%	24.1×	9
FY2028	$9.43B	+18.4%	$46.89	+26.5%	19.0×	4
FY2029	$11.1B	+17.3%	$60.29	+28.6%	14.8×	3
FY2030	$12.6B	+14.2%	$70.72	+17.3%	12.6×	3

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Income statementRevenue, costs, operating income, net income and EPSOpen Balance sheetCash, investments, assets, debt, liabilities and equityOpen Cash flowOperating cash flow, capex, free cash flow, buybacks and dividendsOpen

Sources

Statements, segment revenue, metrics and estimates: Financial Modeling Prep.

Data as of 2026-11-02